Impact of enzalutamide administration on primary prostate cancer volume: A metabolic evaluation by choline positron emission tomography in castration-resistant prostate cancer patients

Clinical Genitourinary Cancer

Volumn 12, Issue 5, 2014, Pages 312-316

  Caffo, Orazio ^a   Maines, Francesca ^a   Donner, Davide ^a   Veccia, Antonello ^a   Chierichetti, Franca ^a   Galligioni, Enzo ^a  

^a SANTA CHIARA HOSPITAL   (Italy)

Author keywords

Choline PET; Enzalutamide; Neo adjuvant therapy

Indexed keywords

ALKALINE PHOSPHATASE; ENZALUTAMIDE; FLUORODEOXYGLUCOSE F 18; PROSTATE SPECIFIC ANTIGEN; ANTINEOPLASTIC AGENT; PHENYLTHIOHYDANTOIN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SIZE; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISEASE COURSE; DRUG UPTAKE; HUMAN; MALE; PROSPECTIVE STUDY; PROSTATE; ANALOGS AND DERIVATIVES; MIDDLE AGED; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RADIOGRAPHY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; HUMANS; MALE; MIDDLE AGED; PHENYLTHIOHYDANTOIN; POSITRON-EMISSION TOMOGRAPHY; PROSTATE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

EID: 84922658492     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2014.03.004     Document Type: Article

References (16)

1. Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004; 10:33-9
2. Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009; 324:787-90
3. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367:1187-97
4. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26:1148-59
5. Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999; 35:1773-82
6. Lawton CA, Bae K, Pilepich M, et al. Long-term treatment sequelae after external beam irradiation with or without hormonal manipulation for adenocarcinoma of the prostate: analysis of radiation therapy oncology group studies 85-31, 86-10, and 92-02. Int J Radiat Oncol Biol Phys 2008; 70:437-41
7. Whittington R, Broderick GA, Arger P, et al. The effect of androgen deprivation on the early changes in prostate volume following transperineal ultrasound guided interstitial therapy for localized carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1999; 44:1107-10
8. Kucway R, Vicini F, Huang R, et al. Prostate volume reduction with androgen deprivation therapy before interstitial brachytherapy. J Urol 2002; 167:2443-7
9. Merrick GS, Butler WM, Wallner KE, et al. Efficacy of neoadjuvant bicalutamide and dutasteride as a cytoreductive regimen before prostate brachytherapy. Urology 2006; 68:116-20
10. Henderson A, Langley SE, Laing RW. Is bicalutamide equivalent to goserelin for prostate volume reduction before radiation therapy? A prospective, observational study. Clin Oncol (R Coll Radiol) 2003; 15:318-21
11. Petit JH, Gluck C, Kiger WS III, et al. Bicalutamide alone prior to brachytherapy achieves cytoreduction that is similar to luteinizing hormone-releasing hormone analogues with less patient-reported morbidity. Urol Oncol 2008; 26: 372-7
12. Gravina GL, Festuccia C, Galatioto GP, et al. Surgical and biologic outcomes after neoadjuvant bicalutamide treatment in prostate cancer. Urology 2007; 70: 728-33
13. Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012; 13:983-92
14. Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013; 368:138-48
15. Taplin ME, Montgomery RB, Logothetis C, et al. Effect of neoadjuvant abiraterone acetate (AA) plus leuprolide acetate (LHRHa) on PSA, pathological complete response (pCR), and near pCR in localized high-risk prostate cancer (LHRPC): Results of a randomized phase II study. Proc Am Soc Clin Oncol 2012; 30:abstract 4521
16. Giovacchini G, Picchio M, Coradeschi E, et al. [(11)C]choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and antiandrogenic therapy. Eur J Nucl Med Mol Imaging 2008; 35:1065-73.